News | April 11, 2021
NATCO receives approval for Ibrutinib tablets from ANDA
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Subscribe To Our Newsletter & Stay Updated
